Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that non-thermal atmospheric pressure plasma may stimulate hair growth through activation of the Wnt/β-catenin signaling pathway, suggesting it could be a potential non-pharmacological treatment for alopecia.

This study found that mesotherapy with dutasteride effectively reduced or stopped hair loss and promoted new hair growth in males with androgenetic alopecia.

This study suggests potential bidirectional causal links between certain sleep traits, like insomnia and reduced sleep duration, and types of alopecia, including alopecia areata; however, these associations did not hold after correcting for multiple tests, warranting cautious interpretation.

This study observed that baricitinib led to significant hair regrowth and improved psychological well-being in severe alopecia areata patients over 48 weeks, with 63.2% achieving a SALT score of ≤20.

This study found that finasteride significantly reduced hirsutism scores in women with idiopathic hirsutism and PCOS, despite no changes in serum androgen levels.

Seborrhea in Parkinson's disease may be linked to hormones, not autonomic impairment.

This study reported that oral minoxidil improved hair density and had an acceptable safety profile in women with androgenetic alopecia.

In this study, transvaginal hydrolaparoscopy ovarian drilling in CC-resistant women with PCOS significantly improved ovulation and pregnancy rates over a six-month period, with 82.9% ovulating and a 70.1% pregnancy rate by the end of the study.

In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents.

This study proposes an innovative treatment for stretch marks by combining skinbooster and microneedling techniques, which induce tissue remodeling and collagen synthesis, and suggests using confocal microscopy as a valuable tool for monitoring skin changes in aesthetic dermatology.

In this study, among patients taking hydroxychloroquine for dermatologic or rheumatologic conditions, none developed symptoms suggestive of SARS-CoV-2 infection despite Italy's high infection rate at the time.

This study found that a combined oral contraceptive containing ethinyl estradiol and desogestrel appeared effective in temporarily treating ovarian hyperandrogenism in adolescents, with reductions in hormone levels and ovarian volume observed.

COVID-19 and related stress may increase hair loss known as Telogen effluvium.

This case study suggests that trichoscopic examination of the beard can aid in diagnosing frontal fibrosing alopecia in men, especially when challenging to differentiate from androgenetic alopecia.

This case study reports a 58-year-old woman experiencing pressure-induced alopecia with concomitant acute telogen effluvium after severe COVID-19, suggesting a potential link between prolonged hospitalization and hair loss.

This narrative review found that ritlecitinib shows consistent effectiveness and a favorable safety profile for treating alopecia areata in clinical trials and real-world settings, with progressive hair regrowth observed, particularly when treatment is initiated early and maintained appropriately.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This real-world study found that baricitinib 4 mg daily was effective in promoting hair regrowth and improving psychological well-being in Italian adults with severe alopecia areata over 48 weeks, with 63.2% of patients achieving significant hair recovery and 9.4% experiencing adverse events.

This study found that baricitinib significantly reduced hair loss in patients with severe alopecia areata, decreasing the mean SALT score from 96.6 to 48 over 24 weeks, with no patients dropping out and only mild adverse events in 12.7% of participants.

This study found that a new propylene glycol-free 5% minoxidil lotion demonstrated good clinical efficacy and very good cosmetic acceptability and tolerability after six months of use in patients with androgenetic alopecia, showing results comparable to traditional formulations containing propylene glycol.

This case report describes a 14-year-old girl with congenital hypotrichosis who experienced improved hair density and thickness after 3 months of treatment with oral minoxidil.

In this study, researchers examined a new propylene glycol-free 5% minoxidil lotion for 6 months among individuals with androgenic alopecia and found it demonstrated good clinical efficacy, with 74% showing a positive response, and very high cosmetic acceptability and tolerability, comparable to traditional formulations.

This review discusses expert consensus on PCOS, emphasizing its impacts and supporting evidence-based treatments, while recommending further research into nutraceutical benefits for managing the condition; it reports no new clinical results.

This review examines the impact of spontaneous premature ovarian insufficiency on women's sexual function and highlights the need for a comprehensive, biopsychosocial approach to management, but presents no new clinical results.

This guideline provides recommendations for prescribing systemic testosterone to women with hypoactive sexual desire disorder, emphasizing safe dosing, monitoring, and the need for informed consent despite regulatory challenges.

This guideline provides evidence-based recommendations for prescribing testosterone therapy to women with hypoactive sexual desire disorder, noting a moderate therapeutic benefit but highlighting limited data and regulatory challenges.

The estradiol valerate/dienogest oral contraceptive helps with heavy periods, may improve acne and symptoms in PCOS, and doesn't affect sexual function.

This study provides a guideline for the safe and effective use of testosterone in women with hypoactive sexual desire disorder, recommending systemic transdermal testosterone for appropriate candidates while highlighting the importance of informed consent and monitoring due to unestablished long-term safety.

In this study, an ultra-low dose combination of estradiol and dydrogesterone significantly reduced hot flushes and improved health-related quality of life among a multi-ethnic population of postmenopausal women, with no notable difference in serious adverse events compared to placebo.

This research found that inhibiting HSP90 in a murine model increased cellular plasticity, suggesting a potential role for HSP90 in cancer progression through enhanced adaptability to stress.